By Buck Daniel –
With each passing day we are closer to having our clients paid with funds from the $650 million dollar settlement agreed to in mid-2014. Unfortunately, as described in the Master Settlement Agreement, the value for each injury category will be slightly less than first estimated. Our payment schedule is estimated to begin around the first half of January and be paid out over the several months following. A final settlement package should be arriving within the next few weeks, so please be on watch for its arrival.
By Buck Daniel
August 14, 2013 – More than 700 Pradaxa cases have now been filed in the Southern District of Illinois before Judge David Herndon. The majority of these cases claim gastrointestinal bleeding injuries, but there have also been many catastrophic bleeding events such as hemorrhagic stroke. Judge Herndon has set “Early Trials” or bellwether trials from the pool of already filed cases to begin on August 11, 2014. By doing so, the conclusion of these trials may set the tone for whatever jury awards or settlements, if any, plaintiffs with similar claims should receive.
Many of our clients’ cases have already been filed in the Pradaxa MDL, and our next step towards resolving your claim is to complete a court ordered Plaintiff’s Fact Sheet (PFS). This PFS includes a brief personal and medical history as a part of the pre-trial discovery phase of the lawsuit. If you have not yet completed, or received, a PFS, please be in contact with our office immediately. Once completed, we can move onto the next important step in this process by evaluating your case with a thorough understanding of your entire background.
Posted by Amber Stanford
June 12, 2012 – More reports were made against the controversial new blood-thinner, Pradaxa, than any other drug on the market last year. And according to the Institute for Safe Medicine Practices’ (ISMP), Pradaxa also topped the list for reports of deaths, hemorrhage, acute renal failure, and stroke. Pradaxa was released as an alternative to the more common Warfarin/Coumadin. However, unlike Warfarin, Pradaxa does not currently have an antidote in the event of excessive bleeding. The FDA launched a review of Pradaxa last December based on bleeding-related side effects, while regulators in Europe and Japan have encouraged stronger warnings. The European Medicines Agency (EMA) has more recently asked for more information regarding specific uses of Pradaxa and how to manage patients using the drug.
Find more information here…
By Shelley Blas
May 31, 2012 – A motion was filed late last night in the product liability case involving Pradaxa.
The petition seeks transfer of nearly a dozen pending cases, and all future claims, to a centralized docket in the U.S. District Court for the Southern District of Illinois. If granted, this will coordinate all federal cases involving this drug.
Pradaxa is prescribed to prevent the formation of blood clots reducing the risk of strokes. However, it has been linked to serious and sometimes fatal bleeding. See article: Pradaxa named in most FDA adverse event reports for deaths, hemorrhage, kidney failure, and stroke
The Nations Law Firm is handling Pradaxa cases. If you or someone you know has suffered a serious bleeding event after using Pradaxa, contact us for a free evaluation by one of our Pradaxa attorneys.